INTEGRATE IIb: A randomized phase III open label study of regorafenib + nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC). This is an ASCO Meeting Abstract ...
Gefitinib plus chemotherapy versus gefitinib alone in untreated patients with EGFR-mutated non–small cell lung cancer and brain metastases (GAP Brain): An open-label, randomized, multicenter, phase 3 ...
This article was co-authored with Emma Myer, a student at Washington and Lee University who studies Cognitive/Behavioral Science and Strategic Communication. In today’s digital age, social media has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results